Sohn Catherine A. 4

Accession 0001555132-26-000006

CIK 0001842295other

Filed

Jan 7, 7:00 PM ET

Accepted

Jan 8, 4:30 PM ET

Size

22.1 KB

Accession

0001555132-26-000006

Form 4

Period: 2026-01-06

Director

Transactions

Exercise/Conversion
Common Stock
2026-01-06$10.42/sh+2,493$25,977→ 2,493 total
Sale
Common Stock
2026-01-06$38.62/sh−2,493$96,270→ 0 total
Exercise/Conversion
Common Stock
2026-01-07$10.42/sh+20,744$216,152→ 20,744 total
Exercise/Conversion
Common Stock
2026-01-07$10.42/sh+2,895$30,166→ 23,639 total
Exercise/Conversion
Common Stock
2026-01-07$10.42/sh+3,281$34,188→ 26,920 total
Sale
Common Stock
2026-01-07$39.11/sh−26,920$1,052,785→ 0 total
Exercise/Conversion
Stock Option (Right to Buy)
2026-01-06−2,493→ 3,211 total
Exercise: $10.42Exp: 2033-03-08→ Common Stock (2,493 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−20,744→ 0 total
Exercise: $10.42Exp: 2031-02-01→ Common Stock (20,744 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−2,895→ 316 total
Exercise: $10.42Exp: 2033-03-08→ Common Stock (2,895 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2026-01-07−3,281→ 5,805 total
Exercise: $10.42Exp: 2034-12-08→ Common Stock (3,281 underlying)

Footnotes (5)

[F1]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive.
[F3]The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.
[F4]The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024.
[F5]The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date.

Documents

1 file

Maze Therapeutics, Inc.

CIK 0001842295

Entity typeother